Medical Developments International (MVP.AX) Stock Price

Medical Developments International Ltd primarily operates in the healthcare industry.

The main competitors of Medical Developments International Ltd in the market include companies such as Pfizer, Johnson & Johnson, and GlaxoSmithKline.

Medical Developments International Ltd is a leading Australian pharmaceutical company specializing in the development and distribution of innovative medical devices and drugs. Founded in 1971, Medical Developments International Ltd has consistently demonstrated a commitment to improving patient outcomes through advanced healthcare products. With a strong focus on research and development, the company has successfully introduced breakthrough solutions in the areas of pain management, respiratory care, and emergency medicine. Over the years, Medical Developments International Ltd has garnered a solid reputation for delivering high-quality and effective medical solutions to healthcare professionals worldwide.

Medical Developments International Ltd has achieved significant milestones since its inception. The company has successfully developed and commercialized innovative medical solutions, positioning itself as a global leader in emergency medical products. Notably, Medical Developments International Ltd has received regulatory approvals for their flagship product, Penthrox, across various countries, including the EU, UK, Australia, New Zealand, and Canada. The company has also forged partnerships with renowned distributors, enabling them to expand their market presence and increase sales. Additionally, Medical Developments International Ltd has continuously invested in research and development to enhance their product portfolio, ensuring they remain at the forefront of medical advancements.

Medical Developments International Ltd (MDI) is primarily present in several countries and regions. The company has a global footprint with significant operations in Australia, New Zealand, and the United States. As an internationally recognized healthcare company, MDI caters to a wide range of markets worldwide, including Europe, Asia, and the Middle East. With its innovative medical solutions and strong market presence, Medical Developments International Ltd continues to expand its reach to meet the growing demand for its products and services across various countries and regions.

Medical Developments International Ltd represents the values of innovation, patient care, and commitment to excellence. With a corporate philosophy centered around improving health outcomes, they strive to develop and provide high-quality medical solutions. By continually researching and investing in cutting-edge technology, Medical Developments International Ltd aims to revolutionize healthcare and create effective treatments for various conditions. Their commitment to integrity, accountability, and ethical practices makes them a trusted leader in the industry. With a focus on improving the well-being of patients, Medical Developments International Ltd is dedicated to delivering innovative solutions that enhance the quality of life for individuals worldwide.

Analysts currently set an average price target of 0.86 AUD for the Medical Developments International stock (median: 0.86 AUD), implying +101.6 % versus the latest price. The consensus is based on 5 analyst ratings.

Medical Developments International Analyst Price Targets 2026

5 analysts currently rate the Medical Developments International stock: 4 recommend buying, 1 holding and 0 selling.

Medical Developments International Analyst Price Targets 2026

Converted at the current exchange rate, the Medical Developments International share trades at 0.26 EUR (0.43 AUD).

The Medical Developments International share (MVP.AX) is listed on 2 stock exchanges, including: ASX (MVP.AX).

Medical Developments International Ltd is an Australian company that offers sustainable solutions in the field of lifesaving, pain relief, and inhalation therapy. The company develops, manufactures, and distributes inhalers, pain relief products, and medical devices. In the lifesaving sector, the company offers the emergency inhalator system Penthrox. This system is used in the treatment of acute pain and injuries such as bone fractures and burns. The Penthrox system is easy to handle and can be quickly deployed by paramedics and emergency physicians on site. This technology is ideal for the military, sports events, and other public gatherings. The company also offers a wide range of pain relief products. The pain reliever Green whistle is a sustainable, hydrogen-based analgesic used in pain therapy. It is easy to use, safe, and effective. The device is ideal for use in hospitals, pain therapy, and palliative care. Inhalation therapy is the company's third business area. The company offers a wide range of inhalation devices specifically developed for people with asthma or other respiratory diseases. With the nebulizer "Nebu-Tech," patients receive precise dosage of the medication, which effectively reaches the lungs. The company has also developed solutions for kindergarten and school medicine to improve the treatment of children and students with asthma. Medical Developments International Ltd places special emphasis on sustainability and environmental friendliness. The company invests in research and development of sustainable technologies and materials to provide eco-friendly products and services. The products are designed for long-term use and can be easily recycled. The well-being of the patient is also a priority in production. No animal components are used, and high standards of quality and safety are ensured. In summary, Medical Developments International Ltd offers a wide range of products that can be used to save lives, alleviate pain, and treat respiratory diseases. The company is focused on sustainability and environmental friendliness and places special emphasis on quality and safety. With the marketing of high-quality products, the company aims to improve the lives of its customers.

The revenue of Medical Developments International is 42.57 M AUD. This figure is based on current financial data and reflects the company's business performance.

The profit of Medical Developments International is 626,000.00 AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Medical Developments International is currently 78.70. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medical Developments International stock.

The price-to-sales ratio (P/S) of Medical Developments International is currently 1.16. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medical Developments International stock.

The Eulerpool Quality Score for Medical Developments International is 5/10.

The ISIN of Medical Developments International is AU000000MVP2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Medical Developments International is A0BLXB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Medical Developments International is MVP.AX. The ticker symbol is used to trade Medical Developments International shares on the stock exchange.